Fundraising FoxAction Potential Venture Capital Ltd. — 2019 Investments
2 investments dated 2019 · listed companies and verified rows first · show all
CVRx develops Barostim, an implantable medical device that uses baroreceptor activation to treat heart failure patients and improve their functional capacity and quality of life.
BiotechHealthtechMedical DevicesAustin, US
Craig Palmer(Executive Officer)inNadim Yared(Executive Officer, Director)inDean Bruhn-Ding(Executive Officer)inJohn Brintnall(Executive Officer)inLiz Galle(Executive Officer)Kevin Hykes(President, Chief Executive Officer & Director)in
Co-investorsABS VenturesNew Enterprise Associates (NEA)Treo Ventures, LlcWindham Capital PartnersYsios CapitalHatteras Venture Partners+1 more
Axon Therapies develops the SAVM procedure, an implant-free catheter-based ablation therapy that targets the right greater splanchnic nerve to reduce overactive sympathetic nerve activity in patients with heart failure with preserved ejection fraction (HFpEF).
HealthtechMedical DevicesNew York, US
Howard R. Levin(Executive Officer, Director)Mark Gelfand(Executive Officer)
BoardPaul LaViolette(Director)in
Board seatImran Eba· per SEC Form D · $15M raise · filed Feb 2019
Co-investorsDeerfield Management CompanyEarlybird Venture CapitalSV Health Investors
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.